Search company, investor...

Corassist Cardiovascular

corassist.com

Founded Year

2003

Stage

Incubator/Accelerator | Alive

Total Raised

$5.25M

About Corassist Cardiovascular

CorAssist is a clinical stage medical device company developing innovative therapeutic products for treating heart failure with preserve ejection fraction. The company's proprietary technology enables the first implantation of devices that directly improves cardiac diastolic function.

Headquarters Location

57 Derech Ha’atzmaut

Haifa, 3303329,

Israel

(+9) 729-955-4500

Missing: Corassist Cardiovascular's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Corassist Cardiovascular's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Corassist Cardiovascular

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Corassist Cardiovascular is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

8,562 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Corassist Cardiovascular Patents

Corassist Cardiovascular has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/22/2005

1/28/2014

Cardiovascular physiology, Cardiology, Cardiac anatomy, Heart diseases, Congenital heart defects

Grant

Application Date

9/22/2005

Grant Date

1/28/2014

Title

Related Topics

Cardiovascular physiology, Cardiology, Cardiac anatomy, Heart diseases, Congenital heart defects

Status

Grant

Latest Corassist Cardiovascular News

Surgeons Implant Revolutionary New Device To Treat Heart Failure

Sep 4, 2017

More than 23 million people worldwide suffer from diastolic heart failure, a condition in which the heart fails to pump sufficient oxygenated blood to meet the body’s needs. Scientists around the globe have been looking for an effective treatment for this condition for years. Now, a unique device developed by Israeli company CorAssist gives new hope to those who suffer from this medical condition. Recently, Israel’s Rambam Hospital was the first to use this device in a 72-year-old Canadian man admitted specifically for this procedure. Heart failure symptoms include shortness of breath, tiredness, swollen legs and limited ability to exercise or perform simple physical tasks. The prognosis of heart failure is poor; more than 40 percent of heart failure patients die within five years of diagnosis. There are several types of heart failure based on the mode of heart dysfunction. Diastolic heart failure occurs when the left ventricle fails to relax and adequately refill with blood (diastolic phase of the heart cycle), resulting in a high filling pressure, congestion and shortness of breath. Approximately half of heart failure patients suffer from diastolic heart failure. The incidence of diastolic heart failure increases with age, and is common among women with hypertension, obesity and diabetes. According to Rambam Hospital, there is currently no effective proven treatment for this condition. Enter Israel’s CorAssist , which developed the CORolla, an elastic device that is implanted inside the left ventricle of the heart by a minimally invasive procedure on a beating heart. The device can improve cardiac diastolic function by applying direct expansion force on the ventricle wall to help the heart fill with blood. Founded in 2003, CorAssist has so afar raised $10 million from venture capital firms Argonaut Ventures, Aurum Ventures and Evergreen Venture Partners. Its technology was invented by company founder Dr. Yair Feld, a cardiologist at Rambam Health Care Campus , together with Dr. Yotam Reisner and Dr. Shay Dubi. Rambam’s Prof. Gil Bolotin and Dr. Arthur Kerner recently led a multi-disciplinary team of cardiologists, heart surgeons, and other Rambam medical professionals in the first clinical implantation surgery on a 72-year old patient. Robert MacLachlan had run out of treatment options in Canada for his diastolic heart failure, when his wife read about the CORolla implant on the Internet. After the surgery, the patient was discharged and is now feeling well back at his home in Canada, a spokeswoman for Rambam tells NoCamels. The CORolla heart implant by CorAssist According to Bolotin, while many potential applicants were interested in the procedure, no one wanted to be the first – except MacLachlan. “This latest medical breakthrough from Rambam represents the best of Israeli health care innovation and commitment to improving the quality of life for all people,” Richard Hirschhaut, National Director of the American Friends of Rambam Medical Center, tells NoCamels. “I am proud that Rambam offers treatments to patients not available anywhere else in the world.” Photos: Courtesy of Rambam Medical Center Facebook Comments

Corassist Cardiovascular Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Corassist Cardiovascular Rank

Corassist Cardiovascular Frequently Asked Questions (FAQ)

  • When was Corassist Cardiovascular founded?

    Corassist Cardiovascular was founded in 2003.

  • Where is Corassist Cardiovascular's headquarters?

    Corassist Cardiovascular's headquarters is located at 57 Derech Ha’atzmaut, Haifa.

  • What is Corassist Cardiovascular's latest funding round?

    Corassist Cardiovascular's latest funding round is Incubator/Accelerator.

  • How much did Corassist Cardiovascular raise?

    Corassist Cardiovascular raised a total of $5.25M.

  • Who are the investors of Corassist Cardiovascular?

    Investors of Corassist Cardiovascular include MedTech Innovator, Evergreen Venture Partners, Aurum Ventures, Ofer Hi-Tech, Argonaut Ventures and 3 more.

  • Who are Corassist Cardiovascular's competitors?

    Competitors of Corassist Cardiovascular include NeoChord, SynCardia Systems, SteadyMed Therapeutics, Sonivate Medical, TRIA Beauty and 10 more.

Compare Corassist Cardiovascular to Competitors

A
Acorn Cardiovascular

Acorn Cardiovascular is a medical device company pursuing treatments for patients with heart failure. Acorn

C
Cleveland Heart

Cleveland Heart has partnered with the Cleveland Clinic to develop the next generation of mechanical cardiac circulatory assist devices with the potential to provide a complete range of treatment options for patients suffering from irreversible end-stage heart failure.

C
CoRepair

CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

C
CathRx

CathRx is a specialist Australian medical device company focusing on the development and commercialisation of a range of cardiac catheters for use in the diagnosis and treatment of heart arrhythmias.

S
Sonivate Medical

Sonivate Medical develops and manufactures technologies to reduce healthcare cost and expand access to diagnostic imaging. The SonicEye is a fingertip-mounted ultrasound probe that enables imaging while leaving both hands free to do work with simultaneous tactile feedback.

C
Cardiola

Cardiola have designed a patented device, the m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient's home.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.